The Indian Pharma Market (IPM) has been valued at Rs 5899 crores in June 2013, registering a growth of 4.8 per cent for the month. Of the top 10 companies this month, Alkem registered a growth of 19.3 per cent, followed by Sun Pharma (11.9 per cent) and Cipla (11.5 per cent). Amongst the top 50, 24 corporates have crossed the growth of IPM in June.
Amongst the top 50 corporates, Eris has the highest growth of 30.3 per cent followed by AstraZeneca at 29.2 per cent and Akumentis at 21.9 per cent. Amongst the 11-20 ranked companies Aristo has shown a high growth at 18.2 per cent followed by Ipca at 14.2 per cent and USV at 10.6 per cent.
| With Bonus Units at Full Value | ||||||||
| Val in Crs | Rank | MAT June -13 | Jun-13 | |||||
| CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 72069 | 100.00 | 9.8 |
5899
|
100.00
|
4.8
|
||
| Abbott + Abbott HC + Novo |
1
|
1
|
4903 | 6.80 | 7.0 |
396
|
6.71
|
2.2
|
| Sun Pharma |
2
|
2
|
3640 | 5.05 | 20.0 |
301
|
5.10
|
11.9
|
| Cipla |
3
|
3
|
3605 | 5.00 | 6.6 |
282
|
4.77
|
11.5
|
| Zydus + Biochem |
4
|
4
|
3216 | 4.46 | 19.6 |
273
|
4.63
|
8.5
|
| Glaxo |
5
|
5
|
3180 | 4.41 | 4.1 |
245
|
4.15
|
-7.7
|
| Ranbaxy |
6
|
6
|
2981 | 4.14 | 6.9 |
229
|
3.88
|
-0.9
|
| Mankind |
7
|
8
|
2617 | 3.63 | 19.5 |
214
|
3.63
|
11.2
|
| Alkem + Cachet + Indchemie |
8
|
7
|
2483 | 3.45 | 12.3 |
219
|
3.70
|
19.3
|
| Pfizer + Wyeth |
9
|
10
|
2213 | 3.07 | 6.1 |
167
|
2.84
|
-5.2
|
| Lupin |
10
|
9
|
2174 | 3.02 | 11.0 |
174
|
2.95
|
3.4
|
| Macleods |
11
|
11
|
1859 | 2.58 | 16.4 |
154
|
2.61
|
8.7
|
| Intas |
12
|
13
|
1784 | 2.48 | 16.4 |
144
|
2.45
|
2.0
|
| Emcure + Zuventus |
13
|
14
|
1693 | 2.35 | 11.0 |
140
|
2.37
|
6.5
|
| Aristo |
14
|
12
|
1674 | 2.32 | 10.7 |
146
|
2.48
|
18.2
|
| Dr. Reddys |
15
|
15
|
1584 | 2.20 | 10.9 |
126
|
2.13
|
1.1
|
| Sanofi-Aventis + Universal |
16
|
16
|
1552 | 2.15 | 7.2 |
125
|
2.12
|
1.4
|
| Glenmark |
17
|
17
|
1435 | 1.99 | 15.0 |
114
|
1.94
|
5.0
|
| Ipca |
18
|
19
|
1311 | 1.82 | 15.6 |
108
|
1.84
|
14.2
|
| Micro + Bal |
19
|
21
|
1305 | 1.81 | 4.6 |
104
|
1.76
|
3.4
|
| USV |
20
|
18
|
1294 | 1.80 | 19.3 |
112
|
1.91
|
10.6
|
Amongst upcoming corporates Corona Remedies has grown at 162.8 per cent, Eris at 30.3 per cent and Akumentis at 21.9 per cent. Astra moves on with second consecutive month on positive growths. Corona Remedies and Tablets India has entered the Rs 200-crore club.
11 regions have outgrown the IPM growth rate. Mumbai has shown the lowest growth in the last 13 months with a growth of -7.7 per cent.
From a therapy perspective nine therapies have outgrown the IPM growth. The anti-infective market has a growth of 7.5 per cent whereas respiratory market is at 17.8 per cent growth. The anti-diabetic market grows at 4.3 per cent and cardiac at 12.9 per cent in chronic business.
|
Val in Crs
|
||||
|
Super Group
|
MAT June13
|
GR%
|
Mth June13
|
GR%
|
| IPM |
72069
|
9.8
|
5899
|
4.8
|
| ANTI-INFECTIVES |
12700
|
8.1
|
987
|
7.5
|
| CARDIAC |
8754
|
11.5
|
728
|
3.3
|
| GASTRO INTESTINAL |
8195
|
10.4
|
711
|
2.8
|
| VITAMINS / MINERALS / NUTRIENTS |
6341
|
9.3
|
545
|
-0.4
|
| RESPIRATORY |
5495
|
8.2
|
379
|
17.8
|
| PAIN / ANALGESICS |
5318
|
7.3
|
440
|
5.6
|
| ANTI DIABETIC |
4877
|
14.4
|
410
|
4.3
|
| GYNAECOLOGICAL |
4643
|
6.6
|
390
|
-0.1
|
| NEURO / CNS |
4403
|
11.0
|
363
|
5.7
|
| DERMA |
3774
|
9.8
|
313
|
1.5
|
| OPHTHAL / OTOLOGICALS |
1290
|
10.1
|
109
|
3.3
|
| HORMONES |
1247
|
14.9
|
101
|
6.6
|
| OTHERS |
984
|
14.8
|
82
|
4.1
|
| ANTI-NEOPLASTICS |
921
|
20.1
|
84
|
26.3
|
| VACCINES |
875
|
4.8
|
75
|
4.7
|
| BLOOD RELATED |
865
|
4.4
|
74
|
-3.5
|
| ANTI MALARIALS |
657
|
12.1
|
46
|
5.9
|
| SEX STIMULANTS / REJUVENATORS |
413
|
15.5
|
34
|
15.5
|
| STOMATOLOGICALS |
318
|
10.1
|
29
|
6.4
|
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech.
AWACS in AIOCD AWACS stands for Advanced Working, Action & Correction System – reflecting the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information. Accurate and faster information flows from the market will help clients grow topline and bottom-line.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val(Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net